BDTX looks worth keeping on the watchlist heading into ASCO.
Black Diamond Therapeutics recently reported positive Phase 2 data for **silevertinib**, its brain-penetrant EGFR inhibitor for frontline NSCLC patients with **EGFR non-classical mutations**. High-level results from the May update: * **Preliminary median PFS: 15.2 months** * **Median DOR not reached** …